ArticleFrontiers in oncology2023

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Demin Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.